Category
Uncategorized
-
Another brewing infectious disease threat and looking to COVID-19 for solutions
The threat of antibiotic resistance continues to grow in 2022. Reporters looking for new angles on how to cover this brewing…
-
New webcast to address overhauling care and limiting costs for patients with diabetes
Last month, the National Clinical Care Commission (NCCC) issued a 192-page report urging an overhaul of diabetes care and an…
-
Avoiding “message fatigue” when reporting on masks and COVID-19
Trying to engage audiences when writing about obtaining and wearing appropriate masks to prevent the spread of COVID-19 can be…
-
One journalist explores concerns surrounding teletherapy for psychedelic mental health treatment
Shayla Love, a senior staff writer at Motherboard (the tech arm of Vice.com), has written several articles about psychedelic drugs used as mental…
-
AHCJ to launch new membership portal
AHCJ is proud to announce that Novi, the new membership portal, is scheduled to go live before the end of…
-
Understanding the FDA’s views on use of digital health technologies in clinical trials
In December 2021, The U.S. Food and Drug Administration released draft guidance for industry and investigators about best practices for acquiring data…
-
ACA hits open-enrollment record, but swift action is needed to prevent rate hikes next year
After a record number of consumers signed up for health insurance coverage under the Affordable Care Act (ACA), Bob Herman…
-
Margarita Birnbaum named new AHCJ core topic leader on health equity
Margarita Birnbaum, a Texas-based independent journalist, storyteller, federally certified court interpreter and translator, joins AHCJ as the new health equity…
-
Covering COVID-19 treatments: One journalist’s personal story and some resources
In mid-January, New York Times reporter Rebecca Robbins shared her personal story of hunting down the antiviral Paxlovid to successfully treat her…
-
Tips for covering Medicare’s plan to limit coverage of controversial Alzheimer’s drug
Medicare’s plan to restrict access temporarily to a controversial new Alzheimer’s drug is worth investigating. Expect to see a flurry…